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Adult primary undifferentiated embryonal sarcoma of the liver (UESL) is a rare disease. While the etiology of UESL
remains largely unknown, association with systemic inflammatory disorders has been observed. Here, we report a
case of UESL in a 46-year-old woman with systemic lupus erythematosus (SLE) and without chronic hepatitis or liver
cirrhosis. Systematic review of the publicly available English language medical literature identified only 27 cases of
UESL in patients aged >45 years and none with SLE. Our patient presented with abdominal pain and had a 2-year
history of SLE. Abdominal ultrasonography and enhanced computed tomography revealed a solid mass in the right
lobe of the liver. Presumptive diagnosis of atypical hepatocellular carcinoma was made and the patient was treated
with segmentectomy of S5 and S4a and cholecystectomy. The final diagnosis of UESL was made according to the
pathology results. Since SLE patients may be at increased risk of malignancy, it is possible that the SLE pathogenesis
may have contributed to the development of UESL in our patient. According to this case, UESL should be
considered when SLE patients present with hepatic space-occupying lesions.
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Undifferentiated (embryonal) sarcoma of the liver
(UESL; also known as malignant mesenchymoma of the
liver) is a malignant hepatic tumor that is composed of
undifferentiated mesenchymal cells. The majority of the
reported cases occurred in children between the ages of
6 and 15 years [1,2], but occasional diagnosis of UESL in
adult patients (defined in the literature as aged >15 years)
have also been reported [3]. UESL in patients aged
45 years or older is extremely rare, and only 27 such
cases have been reported in the English language
medical literature up to 2012. With the exception of two
cases that are not well documented, these cases are
summarized in Table 1 [3-24]. The etiology of this rare
disease remains largely unknown, especially in adult
patients. However, a potential association with inflam-
matory disease has been suggested based upon some* Correspondence: daicl_sj@163.com
1Department of General Surgery, Shengjing Hospital, China Medical
University, Shenyang 110004, Liaoning Province, P R China
Full list of author information is available at the end of the article
© 2013 Jia et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the orcases with co-morbidities, such as CREST syndrome,
malaria, community-acquired pneumonia, cancer-related
chemotherapy, and multiple sclerosis [6,8,12,15,22].
SLE is a relatively common chronic inflammatory
disease that affects multiple organs but only rarely
causes serious liver impairment. While SLE has not been
previously associated with UESL, it is associated with an
increased risk of malignancy, particularly with hepatic
cavernous hemangioma, lymphoma, and hepatocellular
carcinoma (HCC) [25-27]. Herein, we report a new
case of UESL that occurred in a middle-aged female
with SLE. The patient had a medical history of steroid
hormone therapy to treat the SLE but no medications or
co-morbidities related to cancer or liver damage. To
the best of our knowledge, this is the first report of a
concomitant case of UESL and SLE. No distinctive
symptoms, tumor markers, or imaging features were
found and UESL diagnosis was based on surgical
pathology.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.



















R + L 20 × 18 × 15 Rx ext hep None Yes DOD, 5 months None
2 Tanner
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↑ALP, GGT R NA HA ligation +
pump
5-FU - AWD, 8 months CHD
3 Chang
et al. [6]










1983 F 86 RUQA pain,
RUQA mass
Normal R 18 × 12 × 12 Tumorectomy None Yes DOD, 2 months None
5 Forbes
et al. [8]














NA NA NA None None - DOD None
7 Grazi
et al. [9]
1996 F 60 RUQA mass,
dyspepsia
Normal R 22 Rx hep None Yes DOD, 10 months NA
8 Nishio
et al.[3]
2003 F 49 RUQA pain,
general fatigue
NA R 14 × 8 × 8 Rx lob Adm+ Dtic Yes DOD, 29 months None
9 Nishio
et al. [3]





















Normal L 15 × 13 Left lob MAID, RT No ANED, 6 months NA
12 Agaram
et al. [11]
2006 F 50 NA NA NA 17 NA NA No ANED, 8 months NA
13 Scudiere
et al. [12]
2006 F 51 NA ↑ALT, AST R 23 × 16 × 7 Rx lob NA NA NA Community-
acquired
pneumonia



















Table 1 Summary of the clinical features reported for undifferentiated liver embryonal sarcoma in patients aged over 45 years (Continued)
15 Yang
et al. [14]

















R 13 × 12 × 12 Rx hep NA NA NA None
17 Kullar
et al. [15]
2009 F 52 RUQA pain,
RUQA mass





2010 F 53 Abdominal
discomfort
Normal R 13 × 12 × 8 Rx hep None No ANED, 6 months None
19 Massani
et al. [17]
2010 F 47 Upper abdominal
pain
Normal R 8 Rx hep Epi + Ifs; TACE
with Epi
Yes AWD, 29 months None
20 Li et al. [18] 2010 M 63 RUQA pain, fever ↑ALP R 20 × 15 × 15 Rx hep NA Yes DOD, 18 months None
21 Li et al. [18] 2010 M 56 RUQA pain ↑ALP, ALT,
AST, GGT
R 13 × 12 Rx hep TACE with
lipiodol, Epi,
hydroxycamptothecin
Yes DOD, 28 months None
22 Gasljevic
et al. [19]







2011 F 47 Abdominal mass ↑CA-125 L 12 × 10 Left hep MAID, RT Yes AWD, 48 months None
24 Legou
et al. [21]




L 27 × 22 × 10 Tumorectomy NA NA NA None
25 Tanaka
et al. [22]








2012 F 74 Abdominal pain
and fullness,
back pain
Normal L 18 × 15 × 13 Left hep None No ANED, 9 months NA
27 Lightfood
et al. [24]
2012 F 78 Abdominal mass Normal R 16 Partial right
hepatectomy
None No ANED, 6 months NA
28 This report 2013 F 49 Upper abdominal
pain
Normal R 7 × 6 × 5 Rx lob Traditional Chinese
medicine orally
Yes DOD, 12 months SLE
5-FU, 5-fluouracil; Adm, doxorubicin; AFP, α-fetoprotein; ALP, alkaline phosphatase; ALT, alanine aminotransferase; ANED, alive with no evidence of disease; AST, aspartate aminotransferase; AWD, alive with disease;
B-ALL, B-lymphoblastic leukemia; CA-125, carbohydrate antigen 125; CAV, cyclophosphamide + Adm + Vcr; CHD, coronary heart of disease; CREST syndrome, calcinosis, Raynaud phenomenon, esophageal dysmotility,
sclerodactyly, and telangiectasia syndrome; DOD, dead of disease-related cause; Dtic, decarbazine; Epi, epirubicin; F, female; GGT, γ-glutamyl transpeptidase; HA, hepatic artery; HCC, hepatocellular carcinoma; Ifs,
ifosfamide; L, left; Left hep, left hepatectomy; Left lob, left lobectomy; M, male; MAID, Adm + Ifs + Dtic + methylprednisolone; NA, not available; R, right; RT, radiation therapy; RUQA, right upper quadrant abdominal;



















Figure 1 Transverse ultrasound scan of the upper abdomen
showing a non-homogeneous, iso-hypoechoic and solid lesion
in the right lobe of the liver.
Figure 2 Contrast-enhanced CT axial section of the abdomen
showing ahypodense lesion in the right lobe of the liver. The
lesion is differentiated from the surrounding hepatic tissue by
lower enhancement.
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In January 2010, a 46-year-old woman presented with a
complaint of idiopathic upper abdominal pain that had
lasted for about 20 days. Self-report of personal and
medical history indicated no recent weight loss, no
symptoms or diagnoses of hepatitis or other liver dis-
eases, no drug abuse, and no specific family history of
cancer. However, the patient revealed a diagnosis of SLE
from 2 years prior, since which she had remained on a
prednisone (PSL) regimen of 10 mg/day.
Physical examination on admission showed that the
patient was well nourished and had no signs of jaundice,
icteric sclera, spider naevi, or palmar erythema. The car-
diopulmonary examination was unremarkable. Abdom-
inal examination revealed it to be soft and without
tenderness or palpable mass. However, palpation of the
hepatic region elicited pain, so that no further exami-
nation could be performed below the xiphoid and the
right lower costal margin of the liver. Laboratory tests
showed blood cell counts, liver function, renal function,
and coagulation time within the normal ranges. Tests
for hepatitis B and C viruses were negative. Tests for the
tumor markers carcinoembryonic antigen (CEA; general
cancer), α-fetoprotein (AFP; HCC), and cancer antigen
19–9 (CA19-9; gastrointestinal cancer) were normal.
The test for the autoimmune disorder marker antinu-
clear antibody (ANA) was positive at a titer of 1:320.
Tests for deficiencies in the complement system indicated
normal activity, with C3 being 1.08 g/L(0.74-1.4 g/L) and
C4 being 0.186 g/L(0.12-0.36 g/L). Likewise, quantitative
immunoglobulin (Ig) testing indicated that the immune
system status was normal, as indicated by IgA at 3.86 g/L
(0.97-3.2 g/L), IgM at 0.34 g/L(0.4-1.59 g/L), and IgG at
10.10 g/L(6.95-15.15 g/L). No antibodies against double-
stranded DNA, ribonucleoprotein, Smith antigen, SSA/Ro,
SSB/La, SCl-70, or JO-1 were detected.
Abdominal ultrasound examination revealed a 6.3 ×
5.5 cm solid lesion in the right lobe of the liver. The
lesion showed inhomogeneous echogenicity, with iso-
and hypo-echoicareas, and had indistinct boundaries
(Figure 1). Abdominal contrast-enhanced computed to-
mography (CT) revealed an irregularly shaped space-
occupying lesion in the right anterior lobe of the liver
that measured 6.0 × 5.0 cm. During the unenhanced
phase, the lesion appeared slightly hypodense (CT value
of 42 HU); during the hepatic arterial phase, the en-
hancement of the lesion was obviously lower than that
of the surrounding tissues (Figure 2). Delayed scanning
showed that the enhancement of the lesion did gradually
increase but always remained lower than that of the
surrounding tissues. The overall imaging characteristics
of the lesion were non-specific and the differential diag-
noses that were considered included secondary hepatic
neoplasm, biliary neoplasm, and atypical hepatocellularcarcinoma. Colonoscopy and gastroscopy examina-
tions were performed and yielded normal findings.
Similarly, the chest X-ray and whole body bone scan
was normal.
Based upon these collected findings, the initial diagno-
sis was primary liver neoplasm. As such, segmentectomy
of S5 and S4a and cholecystectomy were performed
under general anesthesia. During the operation, a solid
mass with 6 cm diameter was located in the right anter-
ior lobe of the liver. Exploration of the left hepatic lobe
and abdominal cavity found a normal structure and no
other tumors. Finally, a partial hepatectomy was carried
out to remove the entire lesion from the right lobe,
which included a sufficient portion of the normal liver
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status was confirmed as R0.
Histological analysis of the resection specimen defined
the 6.5 × 6 × 5 cm lesion as well circumscribed, lobulated
and soft, with yellowish-brown and grayish-white color-
ation. Observation of a gross cross-sectional area of the
lesion showed dark red coloration and a small variegated
portion. Microscopic examination showed that the
tumor cells were spindle- or polygonal-shaped, arranged
in a fascicular pattern, and distributed diffusely through-
out the mass (yellow arrows); in addition, multinucleate
giant cells (blue arrows), remnants of small bile ducts
(black arrows), and chronic inflammatory cell infiltra-
tion were also detected in the tumor tissue (Figure 3A).
Immunohistochemical staining for cancer markers defined
the tumor as positive for vimentin, alpha-1-antitrypsin
(AAT), and periodic acid-Schiff (PAS) (Figure 3B, 3C, 3D),
but negative for cytokeratin (CK)AE1/AE3, S-100, epithe-
lial membrane antigen (EMA), alpha-smooth muscle actin
(SMA), myogeinc differentiation 1 (Myo D1), CK8/18,
hepatocyte paraffin 1, human melanoma black-45, melan-
A, CD117, synaptophysin, anaplastic lymphoma kinase,
CD21, CD35, CD23, and CD34. The tumor cells were
positive for vimentin and AAT, which indicated that the
tumor was composed of undifferentiated mensenchymal
cells. The immunoreactive negative findings for CK, S-100,
EMA, alpha-SMA, and MyoD1 indicated there was no
epithelium, nervous, smooth muscle, or striate muscleFigure 3 Histological findings and immunohistochemical expression i
or polygonal-shaped with fascicular arrangement (yellow arrows). In additio
(black arrows), and chronic inflammatory cells infiltration are shown in the
analysis of UESL showing positivity for (B) vimentin and (C) AAT (magnifica
(D) Cells containing eosinophilic cytoplasmic granules staining positive fordifferentiation. The immunoreactive negative findings for
the other markers excluded hepatocellular carcinoma,
melanoma, gastrointestinal stromal tumor, neuroendocrine
tumor, lymphoma, and dendritic cell tumor. The final
diagnosis based on these pathology findings was UESL.
The patient recovered from surgery without com-
plication and was discharged on day 12 postsurgery. No
adjuvant chemotherapy or transcatheter arterial chemo-
embolization (TACE) was performed according to the
patient’s insistence on only taking oral traditional
Chinese medicines. At the 6-month follow-up, an
unresectable tumor was detected, but the patient again
refused palliative therapy (chemotherapy or TACE). The
patient died 1 year later.
Discussion
As a rare disease with few case reports in the literature,
the etiology, cellular origin, and carcinogenic mecha-
nisms of UESL remain unclear. In most cases of UESL,
no pre-existing liver disease is detected [28]; however,
some of the middle-aged and elderly patients diagnosed
with UESL also suffered from multiple sclerosis [22],
concomitant coronary heart disease [5], CREST syn-
drome [6], or community-acquired pneumonia [12]. In
addition, some of these patients have a past history
of malaria [8] or cancer, including patients who have
undergone resection for colonic carcinoma [8] or che-
motherapy for ovarian cancer [15]. Interestingly, onlyn UESL. (A) H&E stained sections showing the tumor cells as spindle-
n, multinucleate giant cells (blue arrows), remnants of small bile ducts
tumor tissue (magnification: 100×). (B, C) Immunohistochemistry
tion: 200×). In (B), black arrows indicate the coutnerstained cell nuclei.
PAS are shown (magnification: 400×).
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aged >45 years had hepatitis B cirrhosis and HCC in
the left lobe (Table 1), which may have contributed
to the development of the UESL.
The new UESL adult case described herein was unique
for the concomitant SLE disease status and history of
steroid therapy. The clinical characteristics of SLE-
associated liver disorders include hepatomegaly, jaun-
dice, and elevated liver enzyme levels; it is unknown,
however, whether these complications are directly
induced by the SLE pathogenic process itself, the drugs
used to treat SLE, or secondary thrombotic events
induced by SLE [25-27]. Both benign (for example,
hemangioma) and malignant lesions have been found in
the livers of patients with SLE and may be related to a
localized chronic inflammatory state. Unfortunately,
these hepatic lesions may be difficult to distinguish
radiographically, and it may be necessary to perform a
biopsy to exclude a neoplasm diagnosis.
Review of the middle-aged and elderly UESL cases
reveals some potential distinguishing characteristics
from the UESL pediatric cases. Where the pediatric
cases of UESL show equal distribution among boys and
girls [28], there are more female cases among the
middle-aged and elderly patients with a female-to-male
ratio of 3.5:1 (Table 1). In addition, where the pediatric
UESL cases often present with a large palpable mass
with or without abdominal pain, the middle-aged and
elderly patients often have non-specific symptoms and
signs. The most frequently reported complaints in the
older population are abdominal pain or discomfort and
detection of an abdominal mass. However, in both the
pediatric and older adult populations, the lesions tend to
be located in the right lobe of the liver.
Further consideration of the adult cases in the litera-
ture indicated that most patients have normal laboratory
results and partial increase in the level of serum alkaline
phosphatase (ALP). Only the patients with concomitant
hepatitis-related cirrhosis or HCC showed elevated
serum AFP and another patient with elevated serum
CA-125 [15,20]. According to the reported ultrasound
findings for these patients, >80% of UESL are solid.
However, CT and magnetic resonance imaging analyses
revealed punctate regions that were identified as liqui-
fied necroses and blood clots in one patient [28]. In
the new case described herein, ultrasound examination
revealed an inhomogeneous iso-hypoechoic solid lesion
and CT showed an avacular entity visibly different from
the surrounding hepatic tissues.
The histopathological features of UESL are also
slightly different between the pediatric patients and the
middle-aged and elderly patients. Unlike the UESL of
pediatric patients, that of older patients tends to have a
less prominent myxoid component and show at least apartial smooth muscle phenotype [3]. Moreover, the
older adult UESL are diffusely positive for vimentin and
AAT, and focally positive for cytokeratin, desmin, SMA,
muscle-specific actin, CD68, myoglobin, non-specific
enolase, S-100, and CD34 [18]. It has been reported
that >80% of the UESL tumor cells overexpress p53
and suggested that the p53 pathway may plays a role
in the disease onset in older adult patients [10].
Unfortunately, the limited number of UESL patients
has also hindered attempts to understand the patho-
genesis of this potentially life-threatening disease and to
develop preventive strategies and effective therapies.
Prognosis of UESL remains poor, and the median sur-
vival is <1 year after diagnosis [28]. Currently, the most
effective therapeutic intervention is complete surgical
resection or liver transplantation plus pre- and/or
postoperative systemic chemotherapy [29,30]. Indeed,
there are reports of prolonged survival in UESL patients
(both children and adults) with radical operation
followed by adjuvant chemotherapy [2,29]. Recently,
May et al. reported that five pediatric UESL patients
treated with a uniform approach of resection followed
by adjuvant chemotherapy (VAC therapy) and radiation
(as indicated on a case-by-case basis) achieved disease-
free status and that the median length of their first
remission was 53 months [31]. TACE is another choice
of adjuvant therapy for liver cancer patients. Although
the therapeutic effect of a single TACE application did
not achieve good results for resolving the hypovas-
cularity of most UESL patients, a small case series report
indicated that TACE after complete resection of UESL
improved the survival time [18], suggesting that some
UESL cases might be highly sensitive to TACE. Adding
more cases to the published literature may improve our
ability to diagnose and manage UESL.
Conclusions
In conclusion, we report a case of primary UESL
concomitant with SLE in a middle-aged female pa-
tient without established chronic liver disease. The
patient had no specific symptoms and no distingui-
shing findings for tumor markers or cellular and
tissue structures. Final diagnosis was made by surgical
pathology findings, although the precise etiology of
UESL in this SLE patient remains unknown. It is
possible that the long-term steroid therapy and chronic
immune disorder may have contributed to disease onset
or promoted its progression.
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